Headquartered in Sydney, Omniscient Neurotechnology has secured a fundraise of US$ 30 million in series B funding and launches a neurosurgical planning software, Quicktome. The venture round was held on July 19, 2021, and led by several Australian billionaires, valuing the company at $295 million to date. Omniscient Neurotechnology is developing an artificial intelligence software to examine the networks of electrical connections uncommon to each person’s brain.
About the Company
Omniscient Neurotechnology, also known as o8t, is a Bioinformatic 3-year-old startup founded by Michael Sughrue and Stephane Doyen. It is a brain mapping corporation that is revolutionizing brain care using data. Omniscient creates applications proficient with analyzing “brain networks” created by the electrical intermediaries in a person’s brain by adopting medical imaging and machine training innovations.
The before-mentioned insights illuminate the neural methods that make us human and help professionals in the medical domain understand and diagnose complicated neurological and mental illnesses.
Purpose of Investment
The Sydney-based startup recently launched Quicktom, the world’s first medical device to provide this vital data with neurological care, contributing neurosurgeons brain information before life-changing surgery. With offices globally, Omniscient is a leader in the study of the brain’s connections. With the latest acquisition of funds, the company hopes to intersect the line between generating high-potential, but still largely speculative, technology and knitting those methods into everyday clinical use.
What the CEO has to say
CEO, Omniscient Neurotechnology, Stephen Scheeler, said, “We are excited to receive regulatory approval for Quicktome. This is the first digital-tech mapping program designed to incorporate brain connectome data from neurosurgeons to better patient upshots. Before this, the devices that neurosurgeons have relied on have been of no match for the brain’s complications. Quicktome breaks data down into actionable insights to notify each incision’s impression on the subject. Following its authorization, physicians are now relying on this technology to supervise surgical planning. It is a notable milestone for Omniscient and, more importantly, begins a new age for neurosurgery for patients and physicians.”
For more extensive analysis and Market Intelligence reports feel free to approach us or visit our website: Venture Capital Market Intelligence Reports | VCBay.
We try our best to fact check and bring the best, well-researched and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!
Next Article
[…] Next Article […]